Defalix65 mcg/vial

Defalix 65 mcg/vial is a iv infusion manufactured by Eskayef Pharmaceuticals Ltd. in Bangladesh. Its active ingredient is Difelikefalin Acetate.

Indications

Defalix IV Infusion is indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis.

Pharmacology

Difelikefalin Acetate is a kappa opioid receptor agonist used in the treatment of pruritus associated with chronic kidney disease in patients undergoing hemodialysis.

Dosage & Administration

Recommended dosage is 0.5 mcg/kg. Administer by intravenous bolus injection into the venous line of the dialysis circuit at the end of each hemodialysis treatment। Do not mix or dilute Difelikefalin Acetate prior to administration। Administer within 60 minutes of syringe preparation. If a regularly scheduled hemodialysis treatment is missed, resume Difelikefalin Acetate at the end of the next hemodialysis treatment.

PEDIATRIC USE

: The safety and effectiveness of Difelikefalin Acetate in pediatric patients have not been established.

GERIATRIC USE

: No overall differences in safety or effectiveness of Difelikefalin Acetate have been observed between patients 65 years of age and older and young adult subjects.

Interaction

No clinical studies evaluating the drug interaction potential of Defalix were conducted.

Side Effects

The most common adverse reactions are diarrhea, dizziness, nausea, gait disturbances, including falls, hyperkalemia, headache, somnolence, and mental status change.

Pregnancy & Lactation

The limited human data on use of Difelikefalin Acetate in pregnant women are not sufficient to evaluate a drug-associated risk for major birth defects or miscarriage. There are no data regarding the presence of Difelikefalin Acetate in human milk or effects on the breastfed infant or on milk production.

Precautions & Warnings

Dizziness, Somnolence, Mental Status Changes, and Gait Disturbances

: Dizziness, somnolence, mental status changes, and gait disturbances, including falls, have occurred in patients taking Defalix and may subside over time with continued treatment. Concomitant use of centrally-acting depressant medications, sedating antihistamines and opioid analgesics may increase the likelihood of these adverse reactions and should be used with caution during treatment with Defalix.

Risk of Driving and Operating Machinery

: Dizziness, somnolence, and mental status changes have occurred in patients taking Defalix. Defalix may impair the mental or physical abilities needed to perform potentially hazardous activities such as driving a car and operating machinery. Advise patients not to drive or operate dangerous machinery until the effect of Defalix on a patient’s ability to drive or operate machinery is known.

Overdose Effects

Single doses of Defalix up to 12 times and multiple doses of Defalix up to 5 times the recommended dosage of 0.5 mcg/kg were administered in clinical studies in subjects undergoing HD. A dose-dependent increase in adverse reactions, including dizziness, somnolence, mental status changes, paresthesia, fatigue, hypertension, and vomiting, were observed. In the event of overdosage, provide the appropriate medical attention based on patient’s clinical status. Defalix is primarily eliminated by the kidneys with a low plasma protein binding of approximately 23% to 28% in dialysis patients. Hemodialysis for 4 hours using a high-flux dialyzer effectively cleared approximately 70% to 80% of Defalix from plasma, and Defalix was not detectable in plasma at the end of the second of two dialysis cycles.

Storage Conditions

Do not store above 25°C temperature. Keep away from light and wet place. Keep out of reach of children.

Disclaimer: This information is for reference only. Always consult a registered physician before taking any medicine.